MAOB and Alzheimer disease: Some organoselenium compounds may also modulate the activityof enzymes relevant to neurotransmission, such as acetylcholinesterase(AChE) and monoamine oxidases (MAO). Indeed,selanyl-2,3-dihydrobenzofurans effectively inhibited cerebral MAO-Bactivity in vitro, with compound TFSeB demonstratingthe most pronounced effect. Consideringthat MAO-B inhibitors act as therapeutic agents for AD, reducing oxidativedamage and improving cognitive function, compound TFSeB emerges asa promising candidate for studies focused on developing more effectivetherapies for AD.